SCLC #NEWS#: The @FDA approved a label update to the administration information for Amgen’s DLL3-targeting T-cell engager for certain patients with extensive-stage small cell lung cancer (ES-SCLC). 🔗Learn more: $AMGN

💡What does progress in small cell lung cancer (SCLC) look like? At #WCLC26#, we’re excited to share our latest research including data from across several studies in small cell lung cancer. Learn more:

#NEWS#: At #ESMO26#, Amgen presents late-breaking data for our DLL3-targeting T-cell engager, with findings simultaneously published in @NEJM. These landmark results add to our growing body of evidence across the #SCLC# treatment journey. Read more: $AMGN

🔬 Research to watch at @myESMO’s #ESMO26#. We're sharing new data across small cell lung cancer (SCLC) and our broader T-cell engager pipeline, including late-breaking research. Search for abstracts LBA3, 3821P and 3808O: